PharmaEssentia Corporation
6446
Rangering i aksjer
#1438
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Aksjekurs
$37.20
Markedsverdi
$15.39B
Endring (1 dag)
1.30%
Endring (1 år)
144.58%
Land
TW
Handel PharmaEssentia Corporation (6446)
Kategori
Healthcare
Inntekter for PharmaEssentia Corporation (6446)
Inntekter i Jun 2026 TTM: $659.89M
Ifølge de nyeste økonomiske rapportene til PharmaEssentia Corporation er selskapets nåværende inntekter (TTM) $659.89M. I 2023 hadde selskapet inntekter på $166.40M en økning sammenlignet med inntektene i 2022, som var $93.99M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for PharmaEssentia Corporation fra 2010 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $659.89M | 122.49% |
| 2024 | $296.59M | 78.25% |
| 2023 | $166.40M | 77.03% |
| 2022 | $93.99M | 296.82% |
| 2021 | $23.69M | 19.41% |
| 2020 | $19.84M | 94.10% |
| 2019 | $10.22M | 1,091.15% |
| 2018 | $857.94K | 530.65% |
| 2017 | $136.04K | -19.37% |
| 2016 | $168.73K | -52.08% |
| 2015 | $352.09K | -16.40% |
| 2014 | $421.16K | -82.61% |
| 2013 | $2.42M | 147.06% |
| 2012 | $980.24K | 88.40% |
| 2011 | $520.29K | -71.45% |
| 2010 | $1.82M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 901.94% |
IN
|
